InsiderTrades.com logo
The Gold Grab of the Century
From Colonial Metals   |   Ad
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.
Ankur Dhingra net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Ankur Dhingra Biography and Net Worth

CFO of Summit Therapeutics
Ankur Dhingra is the Chief Financial Officer at Summit Therapeutics Inc.

What is Ankur Dhingra's net worth?

The estimated net worth of Ankur Dhingra is at least $1.37 million as of March 26th, 2024. Mr. Dhingra owns 354,958 shares of Summit Therapeutics stock worth more than $1,370,138 as of April 27th. This net worth estimate does not reflect any other assets that Mr. Dhingra may own. Additionally, Mr. Dhingra receives an annual salary of $530,000.00 as CFO at Summit Therapeutics. Learn More about Ankur Dhingra's net worth.

How old is Ankur Dhingra?

Mr. Dhingra is currently 47 years old. There are 5 older executives and no younger executives at Summit Therapeutics. The oldest executive at Summit Therapeutics is Mr. Robert W. Duggan, Co-CEO & Executive Chairman, who is 79 years old. Learn More on Ankur Dhingra's age.

What is Ankur Dhingra's salary?

As the CFO of Summit Therapeutics Inc., Mr. Dhingra earns $530,000.00 per year. There are 2 executives that earn more than Mr. Dhingra. The highest earning executive at Summit Therapeutics is Dr. Mahkam Zanganeh D.D.S., M.B.A., Co-CEO, President & Director, who commands a salary of $657,810.00 per year. Learn More on Ankur Dhingra's salary.

How do I contact Ankur Dhingra?

The corporate mailing address for Mr. Dhingra and other Summit Therapeutics executives is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. Summit Therapeutics can also be reached via phone at 650-460-8308 and via email at [email protected]. Learn More on Ankur Dhingra's contact information.

Has Ankur Dhingra been buying or selling shares of Summit Therapeutics?

Ankur Dhingra has not been actively trading shares of Summit Therapeutics within the last three months. Most recently, on Tuesday, March 26th, Ankur Dhingra bought 100,000 shares of Summit Therapeutics stock. The stock was acquired at an average cost of $3.75 per share, with a total value of $375,000.00. Following the completion of the transaction, the chief financial officer now directly owns 354,958 shares of the company's stock, valued at $1,331,092.50. Learn More on Ankur Dhingra's trading history.

Who are Summit Therapeutics' active insiders?

Summit Therapeutics' insider roster includes Ankur Dhingra (CFO), Robert Duggan (CEO), Mahkam Zanganeh (CEO), and Maky Zanganeh (COO). Learn More on Summit Therapeutics' active insiders.

Are insiders buying or selling shares of Summit Therapeutics?

In the last year, Summit Therapeutics insiders bought shares 5 times. They purchased a total of 3,131,590 shares worth more than $5,542,117.20. The most recent insider tranaction occured on March, 26th when CEO Mahkam Zanganeh bought 30,000 shares worth more than $112,500.00. Insiders at Summit Therapeutics own 83.7% of the company. Learn More about insider trades at Summit Therapeutics.

Information on this page was last updated on 3/26/2024.

Ankur Dhingra Insider Trading History at Summit Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/26/2024Buy100,000$3.75$375,000.00354,958View SEC Filing Icon  
12/13/2023Buy20,400$2.17$44,268.00254,958View SEC Filing Icon  
3/7/2023Buy196,362$1.05$206,180.10234,558View SEC Filing Icon  
8/16/2022Buy11,557$0.97$11,210.2938,057View SEC Filing Icon  
See Full Table

Ankur Dhingra Buying and Selling Activity at Summit Therapeutics

This chart shows Ankur Dhingra's buying and selling at Summit Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Summit Therapeutics Company Overview

Summit Therapeutics logo
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $3.86
Low: $3.52
High: $3.90

50 Day Range

MA: $4.06
Low: $3.28
High: $5.07

2 Week Range

Now: $3.86
Low: $1.30
High: $5.22

Volume

1,388,933 shs

Average Volume

2,174,994 shs

Market Capitalization

$2.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
The Gold Grab of the Century
From Colonial Metals   |   Ad
When central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.
That's why we have released our Free Precious Metals Investment Guide.